2024-10-09T09:02:51-05:00 2023-12-31 231144520 TAIT WELLER & BAKER LLP 50 SOUTH 16TH STREET SUITE 2900 PHILADELPHIA PA 19102 990 2023-01-01 208774179 DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA INC DRUG 6462157076 40 RECTOR STREET 16TH FLOOR NEW YORK NY 10006 DELALI ATTIPOE NORTH AMERICA DIRECTOR 6462157076 2024-10-09 1 0 HARRISON PEREIRA P00746867 2159798800 2024-10-08 2023 2024-10-15 13:58:12Z DARIN PORTNOY 40 RECTOR STREET 16TH FLOOR NEW YORK NY 10006 4350936 0 X WWW.DNDINA.ORG X 2007 DE THE DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI), NORTH AMERICA SUPPORTS DNDI'S GLOBAL VISION AND MISSION TO DEVELOP NEW DRUGS, OR NEW FORMULATIONS OF EXISTING DRUGS FOR PATIENTS SUFFERING FROM THE MOST NEGLECTED DISEASES. ACTING IN THE PUBLIC INTEREST, DNDI BRIDGES EXISTING R&D GAPS IN ESSENTIAL DRUGS FOR THESE DISEASES BY INITIATING AND COORDINATING DRUG R&D PROJECTS IN COLLABORATION WITH THE INTERNATIONAL RESEARCH COMMUNITY, THE PUBLIC SECTOR, THE PHARMACEUTICAL INDUSTRY, AND OTHER PARTNERS. 8 8 10 8 0 0 3908555 4335949 0 0 13392 14987 9995 0 3931942 4350936 1777205 1714645 0 0 1549692 1621872 0 0 750435 526174 835787 3853071 4172304 78871 178632 1155455 1819761 229562 715236 925893 1104525 X THE MISSION OF DNDI NORTH AMERICA IS TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GLOBAL OBJECTIVES, IN PARTICULAR TO STRENGHTEN AND EXPAND DNDI'S SCIENTIFIC, POLICY ADVOCACY, FUNDRAISING, AND COMMUNICATIONS EFFORTS IN NORTH AMERICA BY (A) PROVIDING FOCUSED SUPPORT FOR SPECIFIC R&D PROJECTS AND BUSINESS/PARTNER DEVELOPMENT ACTIVITIES IN NORTH AMERICA;(B) ACHIEVING CONCRETE POLICY CHANGES IN NORTH AMERICA TO CREATE A MORE FAVORABLE ENVIRONMENT FOR NEEDS-DRIVEN R&D FOR NEGLECTED DISEASES;(C) MOBILIZING PUBLIC AND PRIVATE FUNDS IN NORTH AMERICA TO SUPPORT DNDI'S MISSION;(D) INCREASING DNDI'S PROFILE AND VISIBILITY IN NORTH AMERICA, THEREBY DRAWING GREATER PUBLIC ATTENTION TO THE NEED FOR NEGLECTED DISEASE R&D. 0 0 2321815 1714645 GRANTS TO RESEARCH AND DEVELOPMENT FOR NEGLECTED DISEASES: DNDI NORTH AMERICA RAISES FUNDS TO SUPPORT DNDI'S RESEARCH AND DEVELOPMENT (R&D) ACTIVITIES IN ORDER TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GOAL OF DELIVERING 25 NEW TREATMENTS FOR NEGLECTED PATIENTS BY 2028 AND ESTABLISHING A ROBUST PIPELINE OF NEW POTENTIAL DRUG CANDIDATES. DNDI NOW HAS OVER 30 PROJECTS IN ITS PIPELINE, INCLUDING OVER 20 POTENTIAL NEW CHEMICAL ENTITIES (NCES), AND HAS DELIVERED 12 TREATMENTS OFR SIX DEADLY DISEASES THAT ARE ALREADY IN THE HANDS OF MILLIONS OF PATIENTS. 617706 RAISING PUBLIC AWARENESS AND ADVOCATING FOR NEGLECTED DISEASE R&D:AS PART OF ITS MISSION, DNDI ADVOCATES FOR ENHANCED POLITICAL LEADERSHIP, INCREASED RESOURCES, AND AN ENABLING POLICY ENVIRONMENT TO STIMULATE R&D FOR NEGLECTED DISEASES. DNDI NORTH AMERICA ACTIVELY ADVOCATES FOR SOUND POLICIES, PARTICULARLY IN THE UNITED STATES, THAT WILL ENABLE GREATER NEEDS-DRIVEN R&D, INCLUDING APPROPRIATE INCENTIVES AND FINANCING MECHANISMS, INNOVATIVE REGULATORY PATHWAYS THAT EXPEDITE ACCESS, AND OPEN INNOVATION APPROACHES TO INTELLECTUAL PROPERTY MANAGEMENT THAT ENSURE THE WIDEST POSSIBLE SHARING OF RESEARCH KNOWLEDGE AND DATA. 2939521 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 10 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 1 0 0 NY X X DELALI ATTIPOE 6462157076 40 RECTOR STREET 16TH FLOOR NEW YORK NY 10006 DARIN PORTNOY CHAIR OF THE BOARD 3.00 X X 0 0 0 JOHN LAWRENCE TREASURER 2.00 X X 0 0 0 SHING CHANG SECRETARY 2.00 X X 0 0 0 KRISTINA TORGESON BOARD MEMBER 2.00 X 0 0 0 BENNETT SHAPIRO BOARD MEMBER 2.00 X 0 0 0 AFRICA STEWART BOARD MEMBER 2.00 X 0 0 0 MEENA AHAMED BOARD MEMBER 2.00 X 0 0 0 LUIS PIZARRO BOARD MEMBER 2.00 X 0 0 0 RACHEL COHEN SENIOR ADVISOR, GLOBAL POLICY ADVOCACY & ACCESS 40.00 X 212616 0 62379 ILAN MOSS HEAD OF MEDIA AND CONTENT 40.00 X 154284 0 12590 VISHAL GOYAL SENIOR CLINICAL PROJECT AND MEDICAL MANAGER 40.00 X 131386 0 40300 COLIN FORSYTH SENIOR RESEARCH AND PROJECT MANAGER 40.00 X 113013 0 58932 611299 0 174201 4 0 1 0 0 4335949 4335949 14987 14987 4350936 0 0 14987 1714645 1714645 274995 192496 27500 54999 959267 483986 259990 215291 76011 38459 20506 17046 223052 113054 60002 49996 88547 47816 21251 19480 31925 17239 7662 7024 36901 19927 8856 8118 577040 209341 31000 336699 7130 3850 1711 1569 48000 25920 11520 10560 104451 56404 25068 22979 26970 14564 6473 5933 3370 1820 809 741 4172304 2939521 482348 750435 819629 1792054 276520 24041 4460 3666 54846 0 1155455 1819761 169716 358039 0 357197 59846 0 229562 715236 X 925893 934525 0 170000 925893 1104525 1155455 1819761 178632 0 X 0 1 X 1 0 X 4625074 3737583 4152891 3908555 4335949 20760052 4625074 3737583 4152891 3908555 4335949 20760052 9816302 10943750 2200 679 399 13392 14987 31657 9995 9995 20801704 0.52610 0.57350 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2022 AMOUNT: $ 9,995. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 4350936 0 4350936 0 4350936 4172304 0 4172304 0 4172304 PART X, LINE 2: MANAGEMENT HAS REVIEWED THE TAX POSITIONS FOR EACH OF THE OPEN TAX YEARS (2020-2022) OR EXPECTED TO BE TAKEN ON DNDI NA'S 2023 TAX RETURN AND HAS CONCLUDED THAT THERE ARE NO SIGNIFICANT UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANT TO RECIPIENT IN REGION 1714645 0 0 0 0 0 0 1714645 0 1714645 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH AND DEVELOPMENT PROJECTS FOR NEGLECTED DISEASES. 1714645 WIRE TRANSFER 0 1 0 0 0 0 0 0 0 PART I, LINE 2: THE GRANTEE SIGNS AN ANNUAL GRANT AGREEMENT WHICH REQUIRES ANNUAL FINANCIAL AND NARRATIVE REPORTING. X X X X 0 0 0 0 0 0 0 0 0 RACHEL COHEN SENIOR ADVISOR, GLOBAL POLICY ADVOCA 204498 0 8118 0 0 0 16170 0 46209 0 274995 0 0 0 COLIN FORSYTH SENIOR RESEARCH AND PROJECT MANAGER 108726 0 4287 0 0 0 8539 0 50393 0 171945 0 0 0 VISHAL GOYAL SENIOR CLINICAL PROJECT AND MEDICAL 126392 0 4994 0 0 0 9947 0 30353 0 171686 0 0 0 ILAN MOSS HEAD OF MEDIA AND CONTENT 148409 0 5875 0 0 0 11701 0 889 0 166874 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY BOTH THE BOARD OF DIRECTORS AND THE AUDIT COMMITTEE PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C ONCE THE CONFLICT OF INTEREST POLICY IS SIGNED ANNUALLY BY EMPLOYEES AND BOARD MEMBERS,IT IS THEN REVIEWED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15A THE ORGANIZATION CONDUCTED A REVIEW OF COMPARABLE ORGANIZATIONS TO DETERMINE THE SALARY AND BENEFITS OF THE EXECUTIVE DIRECTOR AND OTHER STAFF COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.